Articles tagged with Seroconversion
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
A new study found that high-dose influenza vaccine significantly improved humoral response in patients with heart failure or prior myocardial infarction. Vaccination remains crucial in preventing influenza-related complications in high-risk populations.
A Moffitt study found that COVID-19 vaccination led to seroconversion in most cancer patients, but with differing antibody response rates among various cancer types and treatments. Patients with blood cancers had lower seroconversion rates compared to those with solid tumors, highlighting the need for personalized immune responses.
Researchers compared seroconversion in nonhospitalized children and adults with mild SARS-CoV-2 infection to identify factors associated with seroconversion. The study found that certain factors were more common in children, while others were more common in adults with mild COVID-19.
A study suggests that immunocompromised patients, particularly organ transplant recipients, require additional COVID-19 vaccine doses to boost antibody levels. The research found that seroconversion rates were significantly lower in these groups compared to healthy individuals, highlighting the need for targeted interventions.
TG1050 has been shown to reach the clinical goals considered a cure for CHB, including elimination of HBsAg and seroconversion. The study achieved these goals in 30% of TG1050-injected mice, supporting the move to a first-in-man study.
A study found that multiple islet autoantibodies predict a high rate of progression to type 1 diabetes, particularly among younger children and females. The researchers analyzed data from three cohort studies involving over 3,000 genetically at-risk children.
A study found that a tissue-cultured smallpox vaccine elicited high levels of seroconversion and an effective booster response in adults, with no severe adverse events reported. The vaccine's safety and immunogenicity were demonstrated in both previously vaccinated and unvaccinated individuals.
A study published in JAMA found that HIV-infected individuals in industrialized countries now have mortality rates similar to the general population in the first 5 years following infection. However, longer-term excess mortality remains evident, with higher risks for older age groups and injection drug users.
A study found that 81.6% of injection drug users in Vancouver had hepatitis C antibodies, with 62 new cases reported among those initially negative. Risk factors for infection included female sex, cocaine use, and frequent needle-exchange program attendance.